RHB Group Research analyst Vijay Natarajan is keeping his “buy” call on Manulife US REIT (MUST) even though he notes that his earlier view of the REIT’s potential recovery in the 2HFY2022 was “misplaced”.
Manulife US REIT
Price target:
RHB Group Research ‘buy’ 43 US cents
Potential recovery in 2HFY2022 misplaced
